Table 3. Follow-up time and events of breast cancer patients by lipid-lowering drug use at recruitment.
| Outcomes assessed | stage I–IV (n = 3189) | stage I–III (n = 3024) | ||
| lipid-loweringdrug use | no lipid-loweringdrug use | lipid-loweringdrug use | no lipid-loweringdrug use | |
| n patients (%) | 305 (9.6) | 2884 (90.4) | 287 (9.5) | 2737 (90.5) |
| Overall mortality: n events (%) | 49 (16.1) | 355 (12.3) | 39 (13.6) | 298 (10.9) |
| Breast cancer-specific mortality: n events (%) | 29 (9.5) | 257 (8.9) | 20 (7.0) | 201 (7.3) |
| Non-breast cancer mortality: n events (%) | 20 (6.6) | 98 (3.4) | 19 (6.6) | 97 (3.5) |
| Follow-up time for mortality: person years (median) | 1552 (5.1) | 15411 (5.3) | 1491 (5.2) | 14748 (5.4) |
| Recurrence: n events (%) | – | – | 34 (11.9) | 353 (12.9) |
| Follow-up time for recurrence: person years (median) | – | – | 1412 (5.2) | 14028 (5.5) |